Announced
Completed
Financials
Sources
Tags
Acquisition
antibody discovery
Biotechnology
Domestic
Canada
Private
Completed
Friendly
Majority
Single Bidder
Synopsis
AbCellera, a technology company that searches, decodes, and analyzes natural immune systems, completed the acquisition of Trianni, a company that specializes in antibody discovery technology using transgenic mice, for $90m. “Trianni marks our fourth and largest strategic technology addition to date. With its technology and team, Trianni amplifies our capability to generate human antibodies and provides a strong foundation for developing increasingly powerful transgenic mouse technologies. Trianni adds a key pillar to our platform, which now includes genetically engineered rodents, microfluidic single-cell screening, repertoire sequencing, AI-powered computation, and bispecific protein engineering. By integrating these technologies, we aim to provide our partners with access to a modern operating system that improves the speed and probability of success of antibody drug development," Carl Hansen, AbCellera CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.